01
Cash & equivalents increased 12.3%
Cash & equivalents changed +12.3% from the comparable as-filed period.
$152.8M→$171.6MComparable → current
· Pharmaceutical Preparations
RESEARCH SNAPSHOTCRESCENT BIOPHARMA, INC.'s latest supported as-filed period reports revenue of $0. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed +12.3% from the comparable as-filed period.
Net income changed -14.0% from the comparable as-filed period.
Operating income changed -25.4% from the comparable as-filed period. The change ranks at the 40th percentile of 5 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
CBIO · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001628280-26-050869SEC ↗8-KJul 30, 2026Period Jul 30, 20260001628280-26-050805SEC ↗4Jul 20, 2026Period Jul 16, 20260001104659-26-085113SEC ↗8-KJul 15, 2026Period Jul 14, 20260001628280-26-048347SEC ↗8-KJul 14, 2026Period Jul 14, 20260001628280-26-048151SEC ↗4Jun 23, 2026Period Jun 22, 20260001628280-26-044893SEC ↗4Jun 23, 2026Period Jun 22, 20260001628280-26-044892SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Jul 16, 2026Filed Jul 20, 2026 | Fairmount Funds Management LLCDirector | Open Market PurchaseIndirect | 853,450 | $15 | $12.4M | Form 4 ↗ |
| Jul 16, 2026Filed Jul 20, 2026 | Fairmount Funds Management LLCDirector | Open Market PurchaseIndirect | 525,897 | $14 | $7.6M | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Research & development changed +60.5% from the comparable as-filed period. The change ranks at the 40th percentile of 5 prior comparable changes.
Stock-based compensation changed -25.7% from the comparable as-filed period. The change ranks at the 20th percentile of 5 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001628280-26-044890